Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Down 51.3% in September

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 196,700 shares, a drop of 51.3% from the September 15th total of 404,300 shares. Based on an average daily volume of 419,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.8% of the shares of the company are short sold. Approximately 0.8% of the shares of the company are short sold. Based on an average daily volume of 419,000 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

An institutional investor recently bought a new position in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. acquired a new position in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned about 0.12% of Anebulo Pharmaceuticals as of its most recent SEC filing. 28.40% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on ANEB. Maxim Group cut Anebulo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anebulo Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Anebulo Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $5.50.

Anebulo Pharmaceuticals Price Performance

Shares of Anebulo Pharmaceuticals stock opened at $2.76 on Wednesday. Anebulo Pharmaceuticals has a 1 year low of $0.80 and a 1 year high of $3.42. The company has a market capitalization of $113.38 million, a P/E ratio of -10.62 and a beta of -0.89. The business has a 50-day moving average of $2.45 and a two-hundred day moving average of $1.83.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its quarterly earnings data on Monday, September 29th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). On average, equities analysts anticipate that Anebulo Pharmaceuticals will post -0.52 EPS for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.